| Gene symbol | C5 | Synonyms | C5D, C5a, C5b, CPAMD4, ECLZB | Type of gene | protein-coding |
| Chromosome | 9 | Map location | 9q33.2 | dbXrefs | |
| Description | complement C5 | ||||
| GTO ID | GTC1297 |
| Trial ID | NCT00709527 |
| Disease | Age-Related Macular Degeneration |
| Altered gene | C5 |
| Therapeutic/Target gene | Target gene |
| Therapy | Aptamer |
| Treatment | ARC1905|Zimura|Avacincaptad Pegol |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase 1 Ascending Dose And Parallel Group Trial To Establish The Safety, Tolerability AND Pharmacokinetic Profile Of Multiple Intravitreous Injections Of ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Multiple Doses Of Lucentis 0.5 mg/Eye, Or With One Induction Dose Of Lucentis 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration |
| Year | 2008 |
| Country | United States |
| Company sponsor | Ophthotech Corporation |
| Other ID(s) | OPH2000 |
| Cohort 1 | |||||||
|
|||||||